Our Business


Nippon Kayaku's main pharmaceutical products are anti-cancer drugs such as bleomycin, and cancer-related drugs, including those to relieve the pain caused by cancer. In addition, the company produces generics and biosimilars, which have become topical recently, and is pursuing initiatives in the field of endovascular treatments (interventional radiology), which place a minimal burden on patients. Nippon Kayaku is also focusing on the development of new drugs using new technology.

With its strength in anti-cancer drugs, Nippon Kayaku believes its main mission is to provide medical institutions with highly reliable information about cancer treatment. The company is focusing on training its oncology medical representatives (MRs). Currently, it has over 400 MRs, and over 100 of these are oncology MRs.

The company operates the Medical Information Service Center (toll-free number provided on this website). It responds to inquiries from healthcare professionals, as well as from patients and their families concerning Nippon Kayaku pharmaceuticals prescribed by medical institutions and health-insurance pharmacies.

Introduction of Main Products

Anti-cancer drugs

Nippon Kayaku's involvement with anti-cancer drugs dates back to 1969, when it released bleomycin. After that, the company has continued its research and development of therapeutic agents for the improvement of cancer treatment. As of December 2018, Nippon Kayaku has launched 40 anti-cancer drugs, including generics.

History of anti-cancer and cancer-related drugs at Nippon Kayaku

The company's strength lies in its extensive line of anti-cancer drugs and expertise.

(as of December, 2018)

Cancer-related drugs

In addition to anti-cancer drugs, Nippon Kayaku also researches, develops, and sells other drugs used in cancer treatment. These typically include a pain relief drug to relieve the pain caused by metastatic bone cancer.


Nippon Kayaku aims to make further contributions to patients, their families, and healthcare professionals through the rapid commercialization of biosimilar pharmaceuticals, which are playing a major role in the treatment of cancer and Autoimmune disease. By providing a wide range of biosimilars, the company hopes to help realize a society where everyone has access to high quality medical care, at any place and time.

History of Biosimilars at Nippon Kayaku

(as of December, 2018)

Generic drugs

Nippon Kayaku is also engaged in the development of generic drugs. Since there are a large number of drugs involved in cancer treatment, including anti-cancer and anti-emetic drugs, in these generic drugs, the company has worked to further expand its lineup of cancer medications.

Interventional Radiology (IVR)

In 2010, IVR become Nippon Kayaku's third main pharmaceutical product area. The company's aim is to further enhance its lineup of embolic materials tailored to target organs, or the condition of the patient and disease. Nippon Kayaku will continue to contribute to society by providing IVR treatments that place minimal physical burden on cancer and other patients.

Other pharmaceuticals

In addition to cancer-related drugs, Nippon Kayaku is engaged in the development and manufacturing of other pharmaceuticals, such as cardiovascular treatments.

Related Information

MINK Web (Japanese site)
Information site for medical professionals (only for medical professionals)

For patients and family members (Japanese site)
Introducing the website related to Nippon Kayaku's products to patients and family members.

Breast cancer info navigator (Japanese site)
A site that provides correct information on breast cancer to general consumers.

SS-info.net (Japanese site)
A site that helps correctly understand a condition called Sjogren's syndrome.

Dry mouth oasis (Japanese site)
A site that publishes commentaries by experts on their various viewpoints regarding dry mouth.

Corporate Vision
Our Business
Corporate Information
Global Netowork
Investor Relations